CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas

Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since bexarotene reduces the expression of CCR4 in CTCL cells and CCL22 to decrease serum CCL22 levels, bexarotene inhibits the migrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Jun, Ohuchi, Kentaro, Amagai, Ryo, Roh, Yuna, Endo, Junko, Chiba, Hiromu, Tamabuchi, Erika, Kambayashi, Yumi, Hashimoto, Akira, Asano, Yoshihide, Fujimura, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233073/
https://www.ncbi.nlm.nih.gov/pubmed/37275413
http://dx.doi.org/10.1002/ski2.222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233073/
https://www.ncbi.nlm.nih.gov/pubmed/37275413
http://dx.doi.org/10.1002/ski2.222

Ejemplares similares